US-based heart health company Kardigan has acquired Prolaio, a clinical intelligence company advancing cardiology research using real-world patient data and insights.
The acquisition aims to advance Kardigan’s research and development capabilities by integrating Prolaio’s sophisticated software and extensive CV data collection.
Prolaio’s platform comprises the US Food and Drug Administration (FDA) approved patient monitoring software, with a large volume of curated CV clinical data sets.
Its analytics are designed to predict heart-related health challenges and assist clinicians in proactive treatment.
By incorporating Prolaio’s platform, Kardigan aims to optimise and advance its late-stage cardiovascular disease (CVD) research, improving outcomes while reducing costs.
Kardigan co-founder, CEO, and chair and Prolaio co-founder Tassos Gianakakos said: “Kardigan and Prolaio were both founded to challenge the status quo in cardiology.
“If we have any shot at radically reducing the time and cost to develop meaningful new medicines and provide better healthcare for patients, biopharma companies today need to fundamentally embrace real-world data and AI-based tools in a way that is fully integrated across R&D.
“By taking a combined approach, we are paving the way to do something that both big pharma and big tech have struggled to successfully implement to date. Together, Kardigan and Prolaio represent a new and exciting type of company focused on heart health.”
The integration of Prolaio’s tech-enabled clinical trial enrichment capabilities is a key aspect of this acquisition.
Prolaio’s platform converts high-density data into specific insights for CV conditions, enhancing clinical study design, increasing statistical power, and reducing overhead.
The connected data platform is expected to transform CV care delivery, enhance patient access to personalised care and improve engagement and satisfaction.
Kardigan’s unique R&D platform, now improved by Prolaio’s tools, aims to deepen understanding of disease mechanisms and patient responses.
The approach streamlines clinical trials, delivering novel therapies to those most likely to benefit while identifying alternative treatments for others.
Prolaio will continue to operate independently, providing real-world insights and services to its biopharma and CV provider partners.
Prolaio’s platform has been rigorously validated with five FDA-cleared algorithms, over four million hours of patient data, and more than 20 issued patents.
It operates in over 26 countries, reinforcing its global impact in the cardiovascular sector.
With Kardigan’s operational scale, Prolaio is well-positioned to extend its reach and impact, offering cost-effective solutions to improve outcomes and access to care.
Kardigan co-founder and CEO and Prolaio co-founder Jay Edelberg said: “We’ve long believed that meaningful data holds significant promise to transform the way we think about and approach therapeutic development.
“Cardiovascular disease is particularly well-positioned to benefit from this approach given the incredible amounts of information we’re able to gather from the heart with today’s technology.
“By expanding our team of dedicated cardiovascular experts and leveraging one another’s unique drug development and technology-focused strengths, we are poised to establish a new and unrivalled understanding of heart health as we work to bring cardiovascular patients closer to the cures they deserve.”
